文献速递炎症性肠病

慢性储袋炎诊断后早期启动生物制剂不影响临床结局

Early Biologic Initiation After Chronic Pouch Inflammation Diagnosis Does Not Impact Clinical Outcomes.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-02-02

本研究评估慢性储袋炎(CPI)诊断后启动生物制剂的时机对临床及内镜缓解的影响。溃疡性结肠炎(UC)行全结直肠切除伴回肠储袋肛管吻合术(TPC-IPAA)者约20%发生CPI,生物制剂常用于CPI但证据有限。研究旨在分析生物制剂启动时机是否影响CPI的临床与内镜缓解。

要点

  • 约20%的UC患者行TPC-IPAA后发生CPI。
  • CPI的生物制剂应答率:阿达木单抗和英夫利西单抗20%-60%,乌司奴单抗50%-80%,维得利珠单抗30%-70%。
  • 本研究评估CPI诊断后生物制剂启动时机对临床及内镜缓解的影响。

核心结论

  • CPI诊断后早期启动生物制剂不影响临床结局。

研究设计与样本

  • 研究设计为评估生物制剂启动时机相对于CPI诊断对临床及内镜缓解影响的临床研究。

主要发现

  • CPI诊断后早期启动生物制剂未改善临床及内镜缓解。

关键数值与推荐

  • 约20%的UC患者行TPC-IPAA后发生CPI。
  • CPI生物制剂临床应答率:阿达木单抗和英夫利西单抗20%-60%,乌司奴单抗50%-80%,维得利珠单抗30%-70%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 20% of patients with ulcerative colitis (UC) who undergo total proctocolectomy (TPC) with ileal pouch-anal anastomosis (IPAA) develop chronic pouch inflammation (CPI).1 Given the involvement of the small bowel in CPI, there is no consensus on whether it should be managed more like UC or Crohn's disease (CD). Despite limited evidence, biologics are often used for CPI with clinical response rates of 20%-60% with adalimumab and infliximab, 50%-80% with ustekinumab, and 30%-70% with vedolizumab.2,3 Earlier biologic therapy has been associated with greater rates of response and favorable long-term outcomes in patients with CD, however not UC.4-7 The impact of earlier initiation of biologic therapy on CPI clinical outcomes has not been elucidated. The aim of this study was to assess whether timing of biologic initiation relative to CPI diagnosis impacts clinical and endoscopic remission.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kayal M, Kohler D, Colombel JF, et al. Early Biologic Initiation After Chronic Pouch Inflammation Diagnosis Does Not Impact Clinical Outcomes. Clin Gastroenterol Hepatol. 2022. PMID: 35123095. doi:10.1016/j.cgh.2022.01.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。